Skip to main content
. Author manuscript; available in PMC: 2020 May 31.
Published in final edited form as: Ther Innov Regul Sci. 2020 Jan 6;54(1):151–157. doi: 10.1007/s43441-019-00039-9

Table 2.

Generic Substitutions Rates for 1 Week in November 2013, Ordered by Generic Substitution Rate.

Therapeutic Class Generic Substitution Rate % (95% CI) Therapeutic Class Generic Substitution Rate % (95% CI)
Thyroid hormones 64 (64 to 64) Cardiac, antiarrhythmic agentsa 97 (97 to 97)
Estrogens and combinations 71 (71 to 72) ARBs/ combinationsa 98 (98 to 98)
Anticonvulsants, hydantoin 72 (71 to 72) Adrenal hormones and combinationsa 98 (98 to 98)
Androgens and combinations 74 (74 to 75) Antipsychoticsa 99 (98 to 99)
Immunosuppressants 82 (82 to 82) Antidepressantsa 99 (98 to 99)
Parathyroid hormones (calcitonin, spray)a 83 (82 to 84) Antiplatelet Agentsa 99 (99 to 99)
Ocular preparations for pressure lowering 85 (84 to 85) Vasodilating Agentsa 99 (99 to 99)
Stimulant, amphetamine type 90 (90 to 90) Antimanic agentsa (lithium) 99 (99 to 99)
Anticonvulsants, succinimidesa 92 (92 to 93) Sympathomimetic agentsa 99 (99 to 99)
Anticoagulants (warfarin) 95 (95 to 96) Bladder muscle relaxantsa 100 (99 to 100)
Anticonvulsants, miscellaneousa 96 (96 to 96) Antiemeticsa 100 (99 to 100)
Vascular 5HTI AGONIST a 96 (96 to 97) Amebicidesa (puromycin) 100 (99 to 100)
Anesthetics, local (lidocaine)a 97 (95 to 98) Antigouta 100 (99 to 100)

Abbreviations: ARBs, angiotensin receptor blocker, 5-hydroxytryptamine; CI confidence interval.

a

Some classes not selected for modeling due to very high GSR (>95%), low total usage, or very mixed product class.